\
&
Contact us
\
&
Contact us
Published on | 1 month ago
Programmes EIC MissionsEurope is experiencing rapid warming leading to significant climate risks, including heat-related health issues, crop stress from drought, water scarcity, and flooding. To address these challenges, the European Commission's EU Mission on Adaptation to Climate Change is seeking innovative solutions. That is why they have joined forces with the EIC accelerator team to publish a challenge that is looking for start-ups and scale-ups who can provide solutions to tackle these climate risks.
This Challenge competition focuses more in particular on deep tech solutions including nature-based solutions (NbS) and engineering approaches reinforced by AI and other Key Enabling Technologies (KET).
You can find more information about the call and the application procedure on this website. Please note there is an info day on friday morning 14 November about all the EIC accelerator challenges. You can watch in online via this webpage.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
